These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
550 related articles for article (PubMed ID: 7023829)
21. Models for assessing the relationship between drug concentration and drug effect in performance horses. Kamerling SG; Owens JG Br Vet J; 1994; 150(6):507-25. PubMed ID: 7850442 [TBL] [Abstract][Full Text] [Related]
22. [Quantitative dependences for expressing the relationship between the pharmacological effect and the pharmacokinetic parameters of drugs]. Mikhaĭlova D; Iamboliev I Eksp Med Morfol; 1982; 21(3):105-10. PubMed ID: 6756890 [No Abstract] [Full Text] [Related]
23. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Muller PY; Milton M; Lloyd P; Sims J; Brennan FR Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825 [TBL] [Abstract][Full Text] [Related]
24. Effect of chirality on pharmacokinetics and pharmacodynamics. Crom WR Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S9-14. PubMed ID: 1530005 [TBL] [Abstract][Full Text] [Related]
25. Analysis of pharmacokinetic-dynamic interrelations with special reference to applications in cardiovascular clinical pharmacology. de Mey C Int J Clin Pharmacol Ther; 1994 Dec; 32(12):665-74. PubMed ID: 7881706 [TBL] [Abstract][Full Text] [Related]
26. Target-mediated drug disposition and dynamics. Mager DE Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model. Deschamps C; Dubruc C; Mentre F; Rosenzweig P Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025 [TBL] [Abstract][Full Text] [Related]
28. In vitro measurements of metabolism for application in pharmacokinetic modeling. Lipscomb JC; Poet TS Pharmacol Ther; 2008 Apr; 118(1):82-103. PubMed ID: 18374419 [TBL] [Abstract][Full Text] [Related]
29. Pharmaco-electroencephalography and pharmacokinetic/pharmacodynamic modeling in basic research: focus on human pharmacology. Valle M; Barbanoj MJ; Jané F Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():129-37. PubMed ID: 12575480 [TBL] [Abstract][Full Text] [Related]
30. [Basic concepts in pharmacology: important terms in pharmacodynamics and pharmacokinetics]. Singer E Onkologie; 2008; 31 Suppl 2():21-4. PubMed ID: 18487864 [TBL] [Abstract][Full Text] [Related]
31. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785 [TBL] [Abstract][Full Text] [Related]
33. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling. Sung JH; Esch MB; Shuler ML Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1063-81. PubMed ID: 20540627 [TBL] [Abstract][Full Text] [Related]
34. Mathematical modeling of drug delivery. Siepmann J; Siepmann F Int J Pharm; 2008 Dec; 364(2):328-43. PubMed ID: 18822362 [TBL] [Abstract][Full Text] [Related]
35. Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations. Lennernäs H Mol Pharm; 2009; 6(5):1429-40. PubMed ID: 19655809 [TBL] [Abstract][Full Text] [Related]